Sylvant

Main information

  • Trade name:
  • Sylvant 100mg powder for concentrate for solution for infusion vials
  • Pharmaceutical form:
  • Powder for solution for infusion (385231004)
  • Administration route:
  • Intravenous (47625008)
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Sylvant 100mg powder for concentrate for solution for infusion vials
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Product summary:
  • BNF code: 08020400; Excipients: Polysorbate (412166009)

Other information

Status

  • Source:
  • eMC
  • Last update:
  • 30-11-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Package leaflet: Information for the patient

SYLVANT 100 mg powder for concentrate for solution for infusion

siltuximab

This medicine is subject to additional monitoring. This will allow quick identification of new safety

information. You can help by reporting any side effects you may get. See the end of section 4 for how

to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important

information for you.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist, or nurse.

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible

side effects not listed in this leaflet. See section 4.

What is in this leaflet

What SYLVANT is and what it is used for

What you need to know before you are given SYLVANT

How SYLVANT is given

Possible side effects

How to store SYLVANT

Contents of the pack and other information

1.

What SYLVANT is and what it is used for

What SYLVANT is

SYLVANT is a medicine that contains the active substance siltuximab.

Siltuximab is a monoclonal antibody (a specialised type of protein) that binds selectively to an antigen

(a target protein) in the body called interleukin-6 (IL-6).

What SYLVANT is used for

SYLVANT is used to treat multicentric Castleman’s disease (MCD) in adult patients who do not have

human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8) infection.

Multicentric Castleman’s disease causes benign tumours (non-cancerous growths) to develop in the

lymph nodes in the body. Symptoms of this disease may include feeling tired, sweating at night,

having a tingling feeling, and loss of appetite.

How SYLVANT works

Patients with MCD produce too much IL-6 and this is thought to contribute to the abnormal growth of

certain cells in lymph nodes. By binding to IL-6, siltuximab blocks its activity and stops abnormal cell

growth. This helps reduce the size of the affected lymph nodes, which reduces the symptoms of the

illness and should help you carry out your normal daily tasks.

2.

What you need to know before you are given SYLVANT

You should not be given SYLVANT if:

You are severely allergic to siltuximab or any of the other ingredients of this medicine (listed in

section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you are given SYLVANT if:

you have an infection at the moment.

you are due to have a vaccination or may need to have one in the near future – this is because

some vaccines should not be given with SYLVANT.

you have high level of fats in your blood (hypertriglyceridaemia) – this is because SYLVANT

may increase these levels. Your doctor may prescribe medicines to correct this.

you have a condition such as stomach ulcer or diverticulitis that may increase the risk of getting

a tear in the stomach or gut (gastrointestinal perforation). Signs of such a tear developing

include stomach pain getting worse, feeling sick (nausea), change in bowel habits and fever – if

you get any of these, contact your doctor right away.

you have liver disease or changes that show up in blood tests of the liver.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist, or nurse before

you are given SYLVANT.

Allergic reactions

Tell your doctor straight away if you have a severe allergic reaction during or after the infusion. Signs

include: difficulty breathing, chest tightness, wheezing, severe dizziness or light-headedness, swelling

of the lips or skin rash.

Infections

You may be more likely to get infections while you are being treated with SYLVANT.

These infections may be serious, such as pneumonia or blood poisoning (also called “sepsis”).

Tell your doctor straight away if you get any signs of infection during treatment with SYLVANT.

Signs include: cough, flu-like symptoms, feeling unwell, red or hot skin, fever. Your doctor may stop

your treatment with SYLVANT straight away.

Children and adolescents

It is not known if SYLVANT is safe and effective in this population, therefore SYLVANT should not

be given to children and adolescents.

Other medicines and SYLVANT

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other

medicines. This includes any other medicines obtained without a prescription, such as vitamins and

herbal medicines.

In particular, tell your doctor or pharmacist if you are taking any of the following medicines:

theophylline, used to treat asthma

warfarin, a blood thinner

cyclosporin, used during and after organ transplants

oral contraceptives, used to prevent pregnancy.

If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are

given SYLVANT.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think that you might be pregnant or are planning to have a baby,

ask your doctor or pharmacist for advice before you are given this medicine.

SYLVANT is not recommended for use during pregnancy. It is not known if SYLVANT may

affect the baby or a pregnant or breast-feeding woman.

In some cases, if you are pregnant and need treatment for MCD, your doctor may advise that the

benefit of taking SYLVANT for your health outweighs the possible risks to your unborn baby.

You must not become pregnant while you are being treated with SYLVANT and for 3 months

after your treatment has finished. You should use effective methods of contraception during this

time.

It is not known if. SYLVANT passes into breast milk. You and your doctor should decide if you

will continue to take SYLVANT, or breast-feed and discontinue SYLVANT.

Driving and using machines

SYLVANT is not likely to affect your ability to drive, cycle, or use any tools or machines.

3.

How SYLVANT is given

SYLVANT will be given to you by your doctor or nurse, in a hospital or clinic.

The recommended dose is 11 milligrams per kilogram of body weight, given once every

3 weeks.

SYLVANT will be given as an “intravenous infusion” (a drip into a vein, usually in your arm).

It will be given slowly over a period of 1 hour.

During the infusion with SYLVANT, you will be monitored for side effects.

You will receive treatment until you and your doctor agree that you will no longer benefit from

the treatment.

If you are given more SYLVANT than you should

As this medicine will be given to you by your doctor or nurse, it is unlikely that you will be given too

much. If you think you have been given too much SYLVANT, tell your doctor or nurse straight away.

There are no known side effects of having too much SYLVANT.

If you forget or miss your SYLVANT appointment

If you forget or miss your appointment to be given SYLVANT, make another appointment as soon as

possible.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The

following side effects may happen with this medicine.

Tell your doctor straight away if you notice the following side effects, as he or she may need to

stop your treatment:

Common (

may affect up to 1 in 10 people):

severe allergic reaction – the signs may include: difficulty breathing, chest tightness, wheezing,

severe dizziness or light-headedness, swelling of the lips or skin rash.

Other side effects include:

Talk to your doctor, pharmacist or nurse if you notice any of the following side effects:

Very common

(may affect more than 1 in 10 people):

drop in the number of white blood cells (neutropenia)

drop in the number of platelets (thrombocytopenia)

itching

rash, itchy skin rash (eczema)

high fat levels in your blood (hypertriglyceridaemia)

high level of 'uric acid' in the blood, which may cause gout

abnormal kidney function test

swelling in the arms, legs, neck or face

high blood pressure

respiratory infections – such as of the nose, sinuses or throat

urinary tract infection

common cold

sore throat

stomach pain or discomfort, constipation, diarrhoea, heartburn, ulcers (sores) in the mouth,

nausea, vomiting

feeling dizzy

headache

joint pain, arm or leg pain

weight gain.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects

not listed in this leaflet.

In the UK,

you can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App

Store.

In Ireland,

you can also report side effects directly via: HPRA Pharmacovigilance, Earlsfort Terrace,

IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, E-mail:

medsafety@hpra.ie

In Malta,

report side effects to: ADR Reporting

Website: www.medicinesauthority.gov.mt/adrportal

By reporting side effects, you can help provide more information on the safety of this medicine.

5.

How to store SYLVANT

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date

refers to the last day of that month. 100 mg vial has a shelf life of 3 years. Do not use if you see

opaque or foreign particles and/or if the solution appears discoloured after reconstitution.

Store in a refrigerator (2°C – 8°C). Do not freeze. Store in the original package in order to protect

from light.

6.

Contents of the pack and other information

What SYLVANT contains

The active substance is siltuximab. Each single-use vial contains 100 mg siltuximab. After

reconstitution the solution contains 20 mg siltuximab per mL.

The other ingredients (excipients) are L-histidine, L-histidine monohydrochloride monohydrate,

polysorbate 80, and sucrose.

What SYLVANT looks like and contents of the pack

SYLVANT is supplied as a glass vial containing a white powder for concentrate for solution for

infusion.

SYLVANT is available in packs containing 1 vial.

Marketing Authorisation Holder

Janssen-Cilag International NV

Turnhoutseweg 30

2340 Beerse

Belgium

Manufacturer

Janssen Biologics B.V.

Einsteinweg 101

2333 CB Leiden

The Netherlands

For any information about this medicine, please contact the local representative of the Marketing

Authorisation Holder:

Ireland

Janssen-Cilag Ltd.

50-100 Holmers Farm Way

High Wycombe

Buckinghamshire HP12 4EG

United Kingdom

Tel: +44 1 494 567 444

Malta

AM MANGION LTD.

Mangion Building, Triq Ġdida fi Triq Valletta

MT-Ħal-Luqa LQA 6000

Tel: +356 2397 6000

United Kingdom

Janssen-Cilag Ltd.

50-100 Holmers Farm Way

High Wycombe

Buckinghamshire HP12 4EG - UK

Tel: +44 1 494 567 444

This leaflet was last revised in 04/2018

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.

---------------------------------------------------------------------------------------------------------------------------

The following information is intended for healthcare professionals only:

This medicinal product is for single use only.

Use aseptic technique.

Calculate the dose, total volume of reconstituted SYLVANT solution required and the number

of vials needed. The recommended needle for preparation is 21-gauge 1½ inch (38 mm).

Infusion bags (250 mL) must contain Dextrose 5% and must be made of polyvinyl chloride

(PVC), or polyolefin (PO), or polypropylene (PP), or polyethylene (PE). Alternatively PE

bottles may be used.

Allow vial(s) of SYLVANT to come to room temperature (15°C to 25°C) over approximately

30 minutes. SYLVANT should remain at room temperature for the duration of the preparation.

Each vial should be reconstituted with 5.2 mL of single-use sterile water for injections to yield a

20 mg/mL solution.

Gently swirl (DO NOT SHAKE OR VORTEX OR SWIRL VIGOROUSLY) the reconstituted

vials to aid the dissolution of the powder. Do not remove contents until all of the powder has

been completely dissolved. The powder should dissolve in less than 60 minutes. Inspect the

vials for particulate matter and discolouration prior to dose preparation. Do not use if visibly

opaque or if foreign particles and/or solution discolouration are present.

Dilute the total volume of the reconstituted solution dose to 250 mL with sterile Dextrose 5%,

by withdrawing a volume equal to the volume of reconstituted SYLVANT from the Dextrose

5%, 250 mL bag. Slowly add the total volume of reconstituted SYLVANT solution to the

250 mL infusion bag. Gently mix.

The reconstituted solution should be kept for no more than 2 hours prior to addition into the

intravenous bag. The infusion should be completed within 6 hours of the addition of the

reconstituted solution to the infusion bag. Administer the diluted solution over a period of

1 hour using administration sets lined with PVC, or polyurethane (PU), or PE, containing a

0.2-micron inline polyethersulfone (PES) filter. SYLVANT does not contain preservatives;

therefore do not store any unused portion of the infusion solution for re-use.

No physical biochemical compatibility studies have been conducted to evaluate the

co-administration of SYLVANT with other medicinal products. Do not infuse SYLVANT

concomitantly in the same intravenous line with other agents.

Any unused product or waste material should be disposed of in accordance with local

requirements.

In order to improve the traceability of biological medicinal products, the tradename and the batch

number of the administered product should be clearly recorded.

There are no news related to this product.